| Trial ID: | L0514 |
| Source ID: | IRCT20160920029889N1
|
| Associated Drug: |
Allopurinol
|
| Title: |
Evaluation of allopurinol efficacy in patients with nonalcoholic fatty liver disease: a randomized, double blind, placebo-controlled trial
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
nonalcoholic fatty liver disease. <br>Fatty (change of) liver, not elsewhere classified;Fatty (change of) liver, not elsewhere classified
|
| Interventions: |
Intervention 1: Intervention group: reception of allopurinol 300 mg (manufacturing Ramopharmin Pharmaceutical Company) once a day, for 4 months. Intervention 2: Control group: reception of placebo (manufacturing faculty of pharmacy) once a day, for 4 mont
|
| Outcome Measures: |
Change in liver steatosis. Timepoint: before the intervention and at the end of the study. Method of measurement: abdominal computed tomography scans-no contrast injection-spiral (liver hounsfield unit and the liver attenuation index (liver hounsfield unit minus spleen hounsfield unit)).;Change in systemic inflammation. Timepoint: before the intervention and at the end of the study. Method of measurement: high sensitivity c-reactive protein.Change in insulin resistance. Timepoint: before the intervention and at the end of the study. Method of measurement: homeostasis model assessment of insulin resistance.;Change in oxidative stress. Timepoint: before the intervention and at the end of the study. Method of measurement: malondialdehyde.;Change in lipid profile. Timepoint: before the intervention and at the end of the study. Method of measurement: triglycerides, total cholesterol, high density lipoprotein, low density lipoprotein.;Change in liver enzymes. Timepoint: before the intervention and at the end of the study. Method of measurement: alanine aminotransferase, aspartate aminotransferase.;Change in anthropometric measurements. Timepoint: before the intervention and at the end of the study. Method of measurement: weight, body mass index, waist circumference, hip circumference, waist to hip ratio.
|
| Sponsor/Collaborators: |
Oroumia University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 years70 years
|
| Phases: |
Phase 3
|
| Enrollment: |
44
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The blocked randomization method; online; by creating the random blocks of 4 and 6 subjects and unique randomization c
|
| Start Date: |
09/01/2018
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of);Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/27877
|
